



NDA 18337/S-034

**SUPPLEMENT APPROVAL**

Taro Pharmaceuticals North America, Inc.  
Attention: Kavita Srivastava  
Executive Director, Regulatory Affairs  
3 Skyline Drive  
Hawthorne, NY 10532

Dear Ms. Srivastava:

Please refer to your Supplemental New Drug Application (sNDA) dated and received February 13, 2015 submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for FeverAll (acetaminophen) 80 mg, 120 mg, 325 mg, and 650 mg Suppositories.

We acknowledge receipt of your amendments dated May 14, July 14 and 16, 2015.

This "Prior Approval" sNDA proposes a package redesign.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be in the "Drug Facts" format (21 CFR 201.66), where applicable and identical to the following:

- 80 mg, 120 mg, 325 mg and 650 mg immediate container (blister) labels and package insert submitted on May 14, 2015
- 50-count 80 mg, 50-count 120 mg, 50-count 325 mg, 50-count 650 mg outer carton labels submitted on July 14, 2015
- 6-count 80 mg, 6-count 120 mg, 6-count 325 mg submitted on July 16, 2015

The FPL should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 18337/S-034.**” Approval of this submission by FDA is not required before the labeling is used.

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jade Pham, Regulatory Project Manager at (301) 796-7031.

Sincerely,

*{See appended electronic signature page}*

Karen Murry Mahoney, M.D.  
Deputy Director  
Division of Nonprescription Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

KAREN M MAHONEY  
08/12/2015